The Food and Drug Administration removed a partial clinical hold on Versartis Inc.'s (Nasdaq: VSAR) new drug application for VRS-317. The stock price leaped $4.30 to close at $18.92.
Partial clinical hold removed on Versartis NDA
July 06, 2015 at 17:02 PM EDT
